SynthesisFrontiers in pharmacology2024
Effects of atropine on choroidal thickness in myopic children: a meta-analysis.
Synthesis in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Effectiveness of orthokeratology in controlling myopia in adolescents aged 6-18 years: a systematic review and meta-analysis.International ophthalmology · 2026Pooled it
- Repeated low-level red-light therapy vs. conventional treatments for myopic control in children: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Impact of atropine on changes in choroidal thickness in children with myopia: a meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Differences in Posterior Ocular Morphology Following Red Light Therapy Versus 0.01% Atropine for Myopia Control: A Randomized Controlled Trial Analysis.Investigative ophthalmology & visual science · 2026Trial
- Effect of 0.01% Atropine on Choroidal Thickness and Ocular Growth in Pre-myopic Children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications.Ophthalmology and therapy · 2026Review
- Reduced myopia progression with low-dose atropine in DIMS non-responders and evidence of altered pupillary light reflex kinetics.Scientific reports · 2026Article
- Impact of Myopia Control Interventions on Choroidal Thickness in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Ophthalmology science · 2026Review
- IMI-Instrumentation for Myopia Management.Investigative ophthalmology & visual science · 2025Review
- Choroidal response to optical defocus as a potential surrogate marker for myopia control effect.International journal of ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atropine is an effective medicine for myopia prevention and control. This meta-analysis was conducted to investigate the effects of atropine on choroidal thickness (ChT) in children with myopia. Methods: Between its inception and 1 June 2023, Medline, Embase, and Web of Science were all searched, and only English literature was included. The choroidal thickness was the primary study outcome. Axial length, standardized equivalent refraction were examined as secondary outcomes. STATA 12.0 was used for data extraction and analysis. Results: A total of 307 eyes were involved in this study to evaluate the effect of atropine on ChT, axial length (AL) and standardized equivalent refraction (SER) in myopic children. Choroidal thickening was significantly higher in the atropine group than in the control group at 1 month (WMD, 6.87 mm, 95% CI, 0.04 to 13.10, Conclusion: Limited evidence suggests that 0.01% atropine causes choroidal thickening in myopic children at 1 month of treatment. In the short term, choroidal thickness may be a predictor of the effectiveness of atropine in controlling myopia in children. 0.01% atropine is effective in controlling myopic progression in terms of SER and AL. Systematic Review Registration: http://www.crd.york.ac.uk/prospero, identifier, CRD42022381195.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.